Cytoskeleton News and Research

RSS

Researchers develop new method for preventing destructive activity of osteoclasts

Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet - Saint-étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability.

12 Feb 2015

Single genomic change can make beneficial bacteria into pathogenic bacteria

We, as most animals, host many different beneficial bacteria. Being beneficial to the host often pays off for the bacteria, as success of the host determines the survival and spread of the microbe. But if bacteria grow too much they may become deadly.

11 Feb 2015

Study reveals how low levels of profilin 1 protein in breast tumours invade other tissues

A new study led by José Javier Bravo-Cordero, Spanish researcher at the Albert Einstein College of Medicine in New York, details how cells with low levels of the profilin 1 protein in breast tumours increase their capacity to metastasise and invade other tissues.

9 Feb 2015

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country.

31 Jan 2015

Bruker Launches BioScope Resolve™ at the Sixth AFM BioMed Conference

Bruker unveiled the BioScope Resolve™, a biological atomic force microscope (bioAFM), at the sixth AFM BioMed Conference. The BioScope Resolve™ features excellent resolution imaging and comprehensive cell mechanics capabilities, and can be used with an inverted optical microscope (IOM).

From Bruker Nano Surfaces and Metrology 17 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

Rice University researchers model dynamic instability of microtubules

New computer models that show how microtubules age are the first to match experimental results and help explain the dynamic processes behind an essential component of every living cell, according to Rice University scientists.

25 Nov 2014

Scientists use innovative exome sequencing strategy to identify new gene associated with ALS

Using an innovative exome sequencing strategy, a team of international scientists led by John Landers, PhD, at the University of Massachusetts Medical School has shown that TUBA4A, the gene encoding the Tubulin Alpha 4A protein, is associated with familial amyotrophic lateral sclerosis (ALS), a fatal neurological disorder also known as Lou Gehrig's Disease.

23 Oct 2014

Researchers discover novel mechanisms of cell migration

During cancer metastasis, immune response or the development of organisms, cells are moving in a controlled manner through the body. Researchers from the Department of Biomedicine at the University of Basel discovered novel mechanisms of cell migration by observing cells moving on lines of connective tissue.

7 Oct 2014

Artificial cells to devour undesirables: an interview with Dr. Takanari Inoue

If junk is not removed, pathological conditions can develop. For example, in one condition, the neutrophil count significantly decreases. Neutrophils remove pathogens and people with a reduced neutrophil count are more prone to infection, especially to rare bacteria that wouldn’t cause infection under normal conditions.

3 Sep 2014

Novogen declares shareholder meeting results

Australia-US biotechnology company, Novogen Ltd., an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia.

13 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

Schizophrenia-linked genetic variations and the developing brain: an interview with Prof. Guo-li Ming

How much is currently known about what happens in the developing brain that puts people at risk of schizophrenia?

11 Aug 2014

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil.

26 Jul 2014

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss.

11 Jul 2014

Researchers discover primordial cancer in primitive and evolutionary old animals

Every year around 450,000 people in Germany are diagnosed with cancer. Each one of them dreams of a victory in the battle against it.

25 Jun 2014

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

18 Jun 2014